CHEMEROW DAVID I. 4

What Happened
David I. Chemerow, a director of AIM ImmunoTech, converted derivative securities into 25,000 shares of common stock on March 12, 2026 (transaction code C). The conversion was reported at $0.00 per share (total dollar value $0). The same date shows a minor disposition of 25 shares (also $0.00). These transactions reflect a conversion of convertible securities into common stock rather than an open-market purchase or sale.

Key Details

• Transaction date(s) and price(s): March 12, 2026 — 25,000 shares acquired at $0.00; 25 shares disposed at $0.00. Transaction code: C (conversion of derivative security).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — Preferred shares are convertible at 1,000 common shares per preferred share, effectively $1.00 per common share; F2 — None.
• Filing timeliness: Form 4 was filed March 16, 2026. The filing date follows the March 12 transaction and appears to be timely under standard Form 4 reporting windows.

Context
A conversion (code C) means a derivative or preferred security was converted into common stock with no cash paid at conversion. The small 25-share disposition is minor and may reflect rounding/fractional adjustments from the conversion; the filing does not indicate a cash sale. As a director (not a 10% owner), this is an internal capital-structure conversion rather than a market buy/sell that would more directly signal personal trading intent.